Trial Profile
A study investigating the effect on testosterone suppression and prostate specific antigen (PSA) levels in patients with metastatic prostate cancer after switching from GnRH agonists to degarelix
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record